News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 371
- Sources here
- 23
- Companies here
- 10
Search results
Stored financial headlines
Active search
371 matching headlines
Ticker or company: AARMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
STAAR Surgical: China Generates More Than Half Of Q2 Revenue As Total Sales Jump 111%
STAAR Surgical reported a 111% year-over-year jump in Q2 2026 net sales to $93.5 million, with China contributing over half of this revenue at $52.3 million. The company saw significant profitability improvements, including a gross margin increase to 74.5% and net income of $8.1 …
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
STAAR Surgical Q2 Sales Surge, Fueled by China as Key Market
STAAR Surgical (NASDAQ: STAA) announced significant Q2 2026 financial results, with net sales reaching $93.5 million, an 111 percent increase year-over-year. This surge was primarily driven by the Chinese market, which accounted for over half of the quarterly revenue. The company also reported improvements …
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
STAAR Surgical Q2 Earnings Call Highlights
Key Points Interested in STAAR Surgical Company? Here are five stocks we like better. STAAR Surgical reported a strong second quarter: Net sales more than doubled to $93.5 million, while the company returned to profitability with $8.1 million in net income and $20 million …
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 CY2026 Numbers But Stock Drops
STAAR Surgical (NASDAQ:STAA) reported strong Q2 CY2026 results, with revenue up 111% year-on-year to $93.54 million, exceeding analyst expectations, and GAAP EPS of $0.16, beating estimates by 12.6%. Despite these positive numbers, the stock dropped 8% immediately after the announcement. The company's operating margin …
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
Earnings Flash (STAA) STAAR Surgical Company Reports Q2 Revenue $93.5M, vs. FactSet Est of $90.6M
STAAR Surgical Company (STAA) reported its Q2 revenue of $93.5 million, surpassing FactSet's estimate of $90.6 million. This financial update indicates a positive performance for the medical equipment company during the second quarter. The article provides a brief overview of the company's recent earnings.
STAA
main company
Sharemaestro market context
Trend signal active
52 weeks -6.0% · Next-week setup negative 40.7%
Here's How Much $1000 Invested In AAR 5 Years Ago Would Be Worth Today
A $1000 investment in AAR (NYSE: AIR) five years ago would be worth $4,269.15 today, reflecting an annualized outperformance of 22.47% compared to the market. This demonstrates the significant impact of compounded returns over time. The company has an average annual return of 33.98% …
AIR
main company
Sharemaestro market context
Trend signal active
52 weeks +91.6%
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aardvark Therapeutics reported its second-quarter 2026 financial results, highlighting $73.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, which is expected to fund operations into late 2027. The company is actively assessing unblinded Phase 3 HERO and OLE data …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Are Aerospace Stocks Lagging AAR (AIR) This Year?
AAR (AIR) has significantly outperformed its aerospace peers and the broader aerospace sector this year, returning 75.7% compared to the sector's 7.7% average. The company holds a Zacks Rank #1 (Strong Buy) due to improving analyst sentiment and earnings estimates. Astronics Corporation (ATRO) is …
AIR
main company
Sharemaestro market context
Trend signal active
52 weeks +91.6%
Why is Aardvark Therapeutics stock surging today?
Aardvark Therapeutics stock surged 11.1% in pre-open trading after reporting better-than-expected Q2 2026 financial results, beating EPS estimates by $0.21. The company also announced a stronger cash position extending into late 2027 and ongoing positive discussions with the FDA regarding its ARD-101 program, all …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Aardvark Therapeutics Q2 Results: Net loss flat at $14.4 million
Aardvark Therapeutics reported a Q2 EPS of $(0.66), surpassing analyst estimates of $(0.91), while its net loss remained flat at $14.4 million compared to the previous year. This performance was largely due to reduced R&D expenses after the halting of ARD-101 trials, although partially …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Form 8K Aardvark Therapeutics Inc For: 11 August By Investing.com
This article reports on the filing of a Form 8K by Aardvark Therapeutics Inc. for August 11. The filing is a standard regulatory disclosure document that companies submit to the SEC. The article lists the company's stock symbol as AARD.
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Hodges Capital Management Inc.'s AAR Corp(AIR) Holding History
The article details Hodges Capital Management Inc.'s investment in AAR Corp (AIR), reporting that as of June 30, 2026, the firm held 132,805 shares valued at $18.98 million, representing 1.27% of its portfolio. The initial purchase occurred in Q2 2026 at an average price …
AIR
main company
Sharemaestro market context
Trend signal active
52 weeks +91.6%
Aardvark Therapeutics (AARD) faces ARD-101 clinical hold but retains $73.9M cash
Aardvark Therapeutics reported a net loss of $14.4 million for Q2 2026 and $36.0 million for the first six months of 2026, driven by R&D and public-company overhead, but maintains $73.9 million in cash, cash equivalents, and short-term investments, expected to fund operations into …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Aardvark Therapeutics (NASDAQ:AARD) Releases Quarterly Earnings Results, Beats Expectations By $0.21 EPS
Aardvark Therapeutics (NASDAQ:AARD) announced its quarterly earnings, reporting a loss of $0.66 per share, which surpassed analyst expectations of a $0.87 loss by $0.21. Despite beating estimates, the company's shares fell by 4.9% to $7.19 during Tuesday trading. Institutional investors have increased their stakes, …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Aardvark Therapeutics Reports Q2 2026 Results, Updates ARD-101 PWS Program and FDA Discussions
Aardvark Therapeutics announced its Q2 2026 financial results, reporting a net loss of $14.4 million and a cash position of $73.9 million, sufficient to fund operations into late 2027. The company is actively engaging with the FDA to resolve a clinical hold on its …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Aardvark to Assess Unblinded Prader-Willi Trial Data in Q3 2026
Aardvark Therapeutics reported its second-quarter 2026 financial results, revealing $73.9 million in cash and short-term investments, which is expected to fund operations into late 2027. The company is currently assessing unblinded Phase 3 HERO and OLE trial data for ARD-101 in Prader-Willi syndrome in …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Aardvark Therapeutics, Inc. Q2 2026: Net loss $14.4M, EPS $(0.66) — 10-Q Summary
Aardvark Therapeutics, Inc. reported a net loss of $14.4 million, or $(0.66) per diluted share, for Q2 2026, consistent with the prior year. Cash and cash equivalents increased to $73.8 million. Clinical trials for ARD-101 and ARD-201 were paused due to cardiac observations, leading …
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%